Interestingly, ibrutinib treatment also promotes an anti-tumor TH1 phenotype of Vγ9Vδ2 T cells via an ITK-dependent mechanism and rescues the dysfunction of autologous Vγ9Vδ2 T cells in CLL patients, resulting in potent cytotoxicity toward malignant B cells (de Weerdt et al., 2018). The gene discussed is ITK; the disease is B-cell chronic lymphocytic leukemia.